117 results
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
9 May 24
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
4:17pm
by higher royalty costs and an increase in product costs from the mix of products sold and the launch of new products.
Research and development (R&D … biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing
8-K
EX-99.1
22l54scwa
13 Mar 24
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
4:16pm
8-K
EX-99.2
gn8goe rax
4 Mar 24
Completion of Acquisition or Disposition of Assets
6:22am
8-K
EX-99.1
kra50u
6 Nov 23
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
4:31pm
8-K/A
EX-99.2
mu6oq vnjz
6 Nov 23
Report of Independent Registered Public Accounting Firm
6:07am
8-K/A
EX-99.1
v97 zf0vf
6 Nov 23
Report of Independent Registered Public Accounting Firm
6:07am
424B5
ne2y deg308dac6
12 Sep 23
Prospectus supplement for primary offering
6:04am
8-K
EX-99.1
b0i5qr ehvg
2 Aug 23
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
4:05pm
424B3
qptxd7sfmac0
26 Jul 23
Prospectus supplement
4:59pm
S-4/A
lhi9k1x6jcfof
24 Jul 23
Registration of securities issued in business combination transactions (amended)
4:42pm
S-4
tp74f2du9pmy8v7
7 Jul 23
Registration of securities issued in business combination transactions
5:03pm
425
tylhivoxllj7eh74
16 Jun 23
Business combination disclosure
5:17pm